TMDX at a glance
TransMedics Group, Inc. (TMDX, SEC CIK 1756262) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on September 10, 2026 and Form 4 insider filings as recently as September 14, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), TransMedics Group, Inc. (TMDX) reported revenue of $605.5 million (up 37.1% from FY2024) and net income of $190.3 million. Diluted EPS was $4.87.
- As of June 30, 2026, 31 institutional investment managers tracked by SignalX reported holding TransMedics Group, Inc. (TMDX) shares worth $1.4 billion in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Weill David on September 11, 2026 of 1,336 shares at $81.63 per share.
- In the last 90 days, TMDX insiders reported 1 open-market purchase ($109K) and 0 open-market sales ($0) on Form 4, a net purchase of $109K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $605.5M
- +37.1% vs prior year
- Insiders · 90 days
- 1 buy · 0 sells
- Net +$109K
- 13F holders
- 31 funds
- $1.4B · +0 vs prior quarter
- Latest 8-K
- Sep 10, 2026
- Item 7.01 · Item 5.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Medical technology company providing OCS platform and NOP services to improve organ transplant therapy for heart, lung, and liver
- New emphasis on NOP expansion with acquisition of Summit Aviation and 22 fixed-wing aircraft to enhance national organ transportation logistics
- Strategic pivot toward integrating comprehensive transplant logistics, including owning aircraft, to become a full-service U.S. organ procurement provider
- Revenue growth to $605.5M in 2025, up 37.1% YoY; total employees 898 worldwide, mostly U.S.-based
- Commenced transition to new corporate headquarters in Somerville, MA, to support expansion and operations consolidation by 2028
Risk Factors
- Leverage risk from $460M Notes issued May 2023, 1.50% interest, maturing June 2028
- Macroeconomic exposure to long-term Somerville lease, $23.9M annual base rent starting 2028, escalating 2-3% annually
- Supply chain risk from $4.0M noncancellable manufacturing purchase commitment through 2029
- Competitive risk from reliance on sales of organ-specific disposable OCS Perfusion Sets and Consoles amid evolving organ transplant tech
- Operational risk in international expansion with $42.9M spent on fixed-wing aircraft for transplant logistics in 2025
Management Discussion & Analysis
- Convertible Senior Notes issued $460M, net proceeds $393.3M after $52.1M capped call costs and $14.6M issuance costs, interest 1.50%
- CIBC credit facility borrowings $60M, interest rate min 3.5% to 4.0% plus spreads, repayment starting July 2026, maturity July 2027
- Cash expected to fund operations, capex, debt service for 12+ months; potential future capital raises may be needed
- Risks include capacity expansion, regulatory approvals, reimbursement, competition, operating cost increases, and new product development
AI summary of the TMDX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $189.9M, up $32.6M YoY from $157.4M, driven by OCS Liver and NOP usage
- Gross margin 60% vs 61% YoY; product margin 77% vs 80%, service margin 35% vs 32%
- Best segment OCS Liver revenue $148.0M vs $115.9M; worst OCS Lung revenue $2.7M vs $4.6M
- Net income $14.7M vs $34.9M; operating income $23.7M vs $36.6M
- Full-year 2026 effective tax rate guidance 25%-27%; tariffs, inflation and supply-chain volatility remain headwinds
Risk Factors
- No risk-factors section provided in submitted excerpt
- Fourth Credit Agreement amendment dated January 8, 2026, indicating changed debt-financing documentation
- No disclosed regulatory, legal, operational, competitive, market, liquidity, currency, or concentration risks in excerpt
AI summary of the TMDX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Regulation FD disclosure furnished under Item 7.01, not deemed filed under Exchange Act Section 18
- No substantive business, financial, or operational information included in the provided excerpt
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Fernando Araujo appointed CFO and Treasurer effective September 21, 2026, succeeding Gerardo Hernandez
- Araujo brings 2023–2026 CFO experience at GE HealthCare’s Advanced Imaging Solutions
Item EX-99.1: Item EX-99.1
- Fernando Araujo becomes CFO September 21, 2026, bringing more than 20 years of GE HealthCare, GE, and 3M finance leadership
- Gerardo Hernandez shifts to Commercial Strategic Advisor, LATAM, aligning finance succession with planned Latin America expansion
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results covered quarter ended June 30, 2026
- Results announced August 4, 2026 through Exhibit 99.1 press release
Item EX-99.1: Item EX-99.1
- Q2 revenue $189.9M, up 21%, led by service revenue growth of 29% to $78.8M
- GAAP operating margin fell to 12.5% from 23.2% as operating expenses rose 49% to $89.5M
Item 5.07: Submission of Matters to a Vote of Security Holders
- All eight director nominees elected, each serving through the 2027 annual meeting
- Executive compensation approved by shareholders on a non-binding advisory basis, with 22,871,647 votes for
AI summaries of TMDX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for TMDX
Don't miss the next TMDX filing
- Alerts as it files. A push when TMDX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut TMDX, by share count.
- Ask anything. An AI agent that reads every TMDX filing and answers with sources.
TMDX alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Weill David | Buy | Sep 11, 2026 | 1,336 | $81.63 |
| TOBIN JAMES R | G | Aug 17, 2026 | 18,000 | - |
| Hassanein Waleed H | A | Jul 10, 2026 | 112,984 | - |
| Corcoran Nicholas | A | Jul 10, 2026 | 17,784 | - |
| Hernandez Gerardo | A | Jul 10, 2026 | 26,153 | - |
| Hassanein Waleed H | A | Jul 10, 2026 | 49,669 | - |
| Hernandez Gerardo | A | Jul 10, 2026 | 17,246 | - |
| Corcoran Nicholas | A | Jul 10, 2026 | 11,727 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $241.6M | $441.5M | $605.5M |
| Gross Profit | - | $262.1M | $362.8M |
| Operating Income | - | $37.5M | $108.6M |
| Net Income | - | $35.5M | $190.3M |
| Gross Margin | - | 59.4% | 59.9% |
| Op. Margin | - | 8.5% | 17.9% |
| Net Margin | - | 8.0% | 31.4% |
| Balance Sheet | |||
| Total Assets | - | $804.1M | $1.1B |
| Equity | $137.2M | $228.6M | $473.1M |
| ROE | - | 15.5% | 40.2% |
| Per Share | |||
| EPS | - | $1.01 | $4.87 |
| Cash Flow | |||
| Operating CF | - | $48.8M | $192.8M |
| CapEx | - | $129.7M | $59.3M |
Source: XBRL data in TransMedics Group, Inc. (TMDX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate TMDX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 31 | $1.37B |
| Q1 2026 | 31 | $2.15B |
| Q4 2025 | 32 | $2.65B |
| Q3 2025 | 33 | $2.47B |
| Q2 2025 | 29 | $2.78B |
| Q1 2025 | 24 | $1.01B |
| Q4 2024 | 25 | $763.7M |
| Q3 2024 | 22 | $700.4M |
- Citadel Advisors LLC+497.2K (+807%)
- BlackRock+303.2K (+6%)
- State Street Corp+100.9K (+8%)
- Dimensional Fund Advisors+93.4K (+18%)
- FMR LLC (Fidelity)+37.1K (+1%)
- Invesco Ltd−643.0K (-62%)
- Two Sigma Investments−316.2K (-97%)
- Goldman Sachs Group−306.5K (-35%)
- T. Rowe Price Group−300.7K (-87%)
- Morgan Stanley−289.0K (-42%)
- Allstate+10.8K
- Marex Group plc+9.9K
- HANCOCK WHITNEY CORP+5.8K
- M&T Bank−2.9K
- Truist Financial−2.5K
- D.E. Shaw & Co−2.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 227 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
TMDX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 14, 2026 | - | - | - |
| 8-K | Sep 10, 2026 | - | Analysis | - |
| 4 | Aug 17, 2026 | - | - | - |
| 10-Q | Aug 4, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 4 | Jul 14, 2026 | - | - | - |
| 4 | Jul 14, 2026 | - | - | - |
| 4 | Jul 14, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 21, 2026 | - | - | |
| 8-K | May 21, 2026 | - | Analysis | |
| 10-Q | May 5, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 5, 2026 | - | Analysis | - |
| SC 13G | Apr 30, 2026 | - | - | |
| SC 13G | Apr 29, 2026 | - | - | |
| 4 | Mar 6, 2026 | - | - | - |
| 4 | Mar 6, 2026 | - | - | - |
| 4 | Mar 4, 2026 | - | - | - |
Related Health Care companies
- AXGN · Axogen, Inc.Electromedical & Electrotherapeutic Apparatus
- BLFS · BIOLIFE SOLUTIONS INCElectromedical & Electrotherapeutic Apparatus
- CV · CapsoVision, IncElectromedical & Electrotherapeutic Apparatus
- CBLL · Ceribell, Inc.Electromedical & Electrotherapeutic Apparatus
- CNMD · CONMED CorpElectromedical & Electrotherapeutic Apparatus
- ELMD · Electromed, Inc.Electromedical & Electrotherapeutic Apparatus
- HYPR · Hyperfine IncElectromedical & Electrotherapeutic Apparatus
- ITGR · Integer Holdings CorpElectromedical & Electrotherapeutic Apparatus
TMDX SEC filings: frequently asked questions
Are TMDX insiders buying or selling?
In the last 90 days, TransMedics Group, Inc. (TMDX) officers, directors and 10% owners reported 1 open-market purchase worth $109,058 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold TMDX stock?
As of June 30, 2026, the largest TransMedics Group, Inc. (TMDX) holders among the 13F filers tracked by SignalX were BlackRock ($371.7 million), FMR LLC (Fidelity) ($341.0 million), Vanguard Portfolio Management LLC ($128.5 million), Vanguard Capital Management LLC ($99.5 million), State Street Corp ($94.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was TMDX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), TransMedics Group, Inc. (TMDX) reported revenue of $605.5 million (up 37.1% from FY2024) and net income of $190.3 million. Diluted EPS was $4.87. The figures come from the XBRL data in the 10-K.
What are the main risks in TMDX's latest 10-K?
In the 10-K filed February 24, 2026, TransMedics Group, Inc. (TMDX) flagged: Leverage risk from $460M Notes issued May 2023, 1.50% interest, maturing June 2028. Macroeconomic exposure to long-term Somerville lease, $23.9M annual base rent starting 2028, escalating 2-3% annually. (AI summary of the Risk Factors section.)
What did TMDX report in its latest 8-K?
TransMedics Group, Inc. (TMDX) filed an 8-K on September 10, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 5.02 (Departure/Appointment of Directors or Principal Officers). Regulation FD disclosure furnished under Item 7.01, not deemed filed under Exchange Act Section 18.
What are the latest TMDX SEC filings?
TransMedics Group, Inc. (TMDX) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on September 10, 2026 and a Form 4 insider filing on September 14, 2026.
What is TMDX's SEC CIK number?
TransMedics Group, Inc. (TMDX)'s SEC Central Index Key (CIK) is 1756262. EDGAR lists every TMDX filing under that number.
Ask anything about TMDX
The research agent reads TMDX's filings, financials, insider trades and 13F holders, then answers with sources.